secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001493152-25-005802
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasmus MC Safety Committee approves Phase 2 study of Ampligen + Imfinzi for late-stage pancreatic cancer
--------------------------------------------------------------------------------

- Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
- Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
- CEO Tom Equels and Prof. van Eijck discussed milestone in Virtual Investor segment.
- Study is investigator-initiated, single-center at Erasmus MC in the Netherlands.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315225005802/0001493152-25-005802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315225005802/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer